Unfolded annealing molecular dynamics conformers for wild-type and disease-associated variants of alpha-synuclein show no propensity for beta-sheetformation — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Unfolded annealing molecular dynamics conformers for wild-type and disease-associated variants of alpha-synuclein show no propensity for beta-sheetformation
Biological Sciences Department, California State Polytechnic University Pomona, Pomona CA 91768
,
Biological Sciences Department, California State Polytechnic University Pomona, Pomona CA 91768
,
Department of Chemistry at Lakehead University and Thunder Bay Regional Research Institute, Thunder Bay ON, Canada P7B 5E1
1 Biological Sciences Department, California State Polytechnic University Pomona, Pomona CA 91768
2 Biological Sciences Department, California State Polytechnic University Pomona, Pomona CA 91768
3 Department of Chemistry at Lakehead University and Thunder Bay Regional Research Institute, Thunder Bay ON, Canada P7B 5E1
Aggregation of alpha-synuclein leads to the formation of Lewy bodies in the brains of patients affected by Parkinson's disease (PD). Native human alpha-synuclein is unfolded in solution but assumes a partial alpha-helical conformation upon transient binding to lipid membranes. Annealing Molecular Dynamics (AMD) was used to generate a diverse set of unfolded conformers of free monomeric wild-type alpha-synuclein and PD-associated mutants A30P and A53T. The AMD conformers were compared in terms of secondary structure, hydrogen bond network, solvent-accessible surface per residue, and molecular volume. The objective of these simulations was to identify structural properties near mutation sites and the non-amyloid component (NAC) region that differ between wild- type and disease-associated variants and may be associated to aggregation of alpha- synuclein. Based on experimental evidence, a hypothesis exists that aggregation involves the formation of intermolecular beta sheets. According to our results, disease-associated mutants of alpha-synuclein are no more propense to contain extended beta regions than wild-type alpha-synuclein. Moreover, extended beta structures (necessary for beta sheet formation) were not found at or around positions 30 and 53, or the NAC region in any unfolded conformer of wild-type, A30P or A53T alpha-synuclein, under the conditions of the simulations. These results do not support the hypothesis that the mutant's higher propensity to aggregation results solely from changes in amino acid sequence leading to changes in secondary structure folding propensity.
KeywordsAlpha-SynucleinParkinson's DiseaseLewy Body FormationBeta Sheet FormationUnfoldingMolecular Simulations
Clayton, D.F. and George, J.M. (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. Journal of Neuroscience Research, 58, 120-129. doi:10.1002/(SICI)1097-4547(19991001)58:1 3.0.CO;2-E
Bueler, H. (2009) Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson’s disease. Experimental Neurology, 218, 235-246.
Zhou, H.Y. and Chen, S.D. (2005) Parkin, Parkin substrates and Parkinson's disease. Progress in Biochemistry and Biophysics, 32, 912-916.
Dekker, M.C.J. et al. (2003) Parkinson’s disease: Piecing together a genetic jigsaw. Brain, 126, 1722-1733. doi:10.1093/brain/awg172
Hattori, N. et al. (2000) Autosomal recessive juvenile parkinsonism: A key to understanding nigral dege- neration in sporadic Parkinson’s disease. Neuropathology, 20, S85-S90. doi:10.1046/j.1440-1789.2000.00312.x
Wszolek, Z.K. and Markopoulou, K. (1999) Molecular genetics of familial parkinsonism. Parkinsonism & Related Disorders, 5, 145-155. doi:10.1016/S1353-8020(99)00030-9
Spillantini, M.G. et al. (1997) Alpha-synuclein in Lewy bodies. Nature, 388, 839-840. doi:10.1038/42166
Sit, S.Y. (2000) Dopamine agonists in the treatment of Parkinson’s disease—Past, present and future. Current Pharmaceutical Design, 6, 1211-1248. doi:10.2174/1381612003399581
Khan, A. et al. (2005) Metals accelerate the formation and direct the structure of amyloid fibrils of NAC. Journal of Inorganic Biochemistry, 99, 1920-1927. doi:10.1016/j.jinorgbio.2005.06.018
Lashuel, H.A. et al. (2000) Protofilaments, filaments, ribbons, and fibrils from peptidomimetic self-assembly: Implications for amyloid fibril formation and materials science. Journal of the American Chemical Society, 122, 5262-5277. doi:10.1021/ja9937831
Jellinger, K.A. (2007) Morphological substrates of parkinsonism with and without dementia: A retrospective clinico-pathological study. Journal of Neural Transmission-Supplement, 72, 91-104.
Cabedo, N. et al. (2009) An overview on benzylisoquinoline derivatives with dopaminergic and serotonergic activities. Current Medicinal Chemistry, 16, 2441-2467. doi:10.2174/092986709788682100
Montastruc, J.L. et al. (1999) Treatment of Parkinson’s disease should begin with a dopamine agonist. Movement Disorders, 14, 725-730. doi:10.1002/1531-8257(199909)14:5 3.0.CO;2-L
Gottwald, M.D. et al. (1997) New pharmacotherapy for Parkinson’s disease. Annals of Pharmacotherapy, 31, 1205-1217.
Uitti, R.J. and Ahlskog, J.E. (1996) Comparative review of dopamine receptor agonists in Parkinson's disease. Cns Drugs, 5, 369-388. doi:10.2165/00023210-199605050-00006
Tofaris, G.K. and Spillantini, M.G. (2007) Physiological and pathological properties of alpha-synuclein. Cellular and Molecular Life Sciences, 64, 2194-2201. doi:10.1007/s00018-007-7217-5
Ulmer, T.S. et al. (2005) Structure and dynamics of micelle-bound human alpha-synuclein. Journal of Biological Chemistry, 280, 9595-9603. doi:10.1074/jbc.M411805200
Dedmon, M.M. et al. (2005) Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. Journal of the American Chemical Society, 127, 476-477. doi:10.1021/ja044834j
Bertoncini, C.W. et al. (2005) Familial mutants of alpha-synuclein with increased neurotoxicity have a destabilized conformation. Journal of Biological Chemistry, 280, 30649-30652. doi:10.1074/jbc.C500288200
I.F. Tsigelny, et al. (2007) Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. FEBS Journal, 274, 1862-1877. doi:10.1111/j.1742-4658.2007.05733.x
Krieger, E. et al. (2004) Making optimal use of empirical energy functions: Force-field parameterization in crystal space. Proteins, 57, 678-683. doi:10.1002/prot.20251
Kabsch, W. and Sander, C. (1983) Dictionary of protein secondary structure: Pattern recognition of hydro- gen-bonded and geometrical features. Biopolymers, 22, 2577-2637. doi:10.1002/bip.360221211
Krieger, E. et al. (2002) Increasing the precision of comparative models with YASARA NOVA—A self-parameterizing force field. Proteins, 47, 393-402. doi:10.1002/prot.10104
Uversky, V.N. et al. (2001) Evidence for a partially folded intermediate in alpha-synuclein fibril formation. Journal of Biological Chemistry, 276, 10737-10744. doi:10.1074/jbc.M010907200
Neal, S. et al. (2003) Rapid and accurate calculation of protein H-1, C-13 and N-15 chemical shifts. Journal of Biomolecular Nmr, 26, 215-240. doi:10.1023/A:1023812930288
Bodner, C.R. et al. (2010) Differential phospholipid binding of alpha-synuclein variants implicated in Parkinson’s disease revealed by solution NMR spectroscopy. Biochemistry, 49, 862-871. doi:10.1021/bi901723p
Chandra, S. et al. (2003) A broken alpha-helix in folded alpha-synuclein. Journal of Biological Chemistry, 278, 15313-15318. doi:10.1074/jbc.M213128200
Fernandez, C.O. et al. (2004) NMR of alpha- synuclein-polyamine complexes elucidates the me- chanism and kinetics of induced aggregation. Embo Journal, 23, 2039-2046.
Georgieva, E.R. et al. (2010) The Lipid-binding Domain of Wild Type and Mutant alpha-Synuclein compactness and interconversion between the broken and extended helix forms. Journal of Biological Chemistry, 285, 28261-28274. doi:10.1038/sj.emboj.7600211
Sasakawa, H. et al. (2007) Ultra-high field NMR studies of antibody binding and site-specific phosphorylation of alpha-synuclein. Biochemical and Biophysical Research Communications, 363, 795-799. doi:10.1016/j.bbrc.2007.09.048
Wu, K.P. et al. (2008) Characterization of conforma- tional and dynamic properties of natively unfolded human and mouse alpha-synuclein ensembles by NMR: Implication for aggregation. Journal of Molecular Biology, 378, 1104-1115. doi:10.1016/j.jmb.2008.03.017
Wolozin, B. and Golts, N. (2002) Iron and Parkinson’s disease. Neuroscientist, 8, 22-32. doi:10.1177/107385840200800107
Golts, N. et al. (2002) Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. Journal of Biological Chemistry, 277, 16116-16123. doi:10.1074/jbc.M107866200
Rasia, R.M. et al. (2005) Structural characterization of copper(II) binding to alpha-synuclein: Insights into the bioinorganic chemistry of Parkinson’s disease. Proceedings of National Academy Sciences of U.S.A., 102, 4294-4299. doi:10.1073/pnas.0407881102
Latawiec, D. et al. (2010) Modulation of alpha-synuclein aggregation by dopamine analogs. Plos One, 5, e9234. doi:10.1371/journal.pone.0009234
Gatto, N.et al. (2009) Alpha-Synuclein repeat polymorphisms and pesticide exposure in Parkinson's disease. Epidemiology, 20, S124-S124. doi:10.1097/01.ede.0000362429.51721.26
Betarbet, R. et al. (2006) Intersecting pathways to neurodegeneration in Parkinson's disease: Effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiology of Disease, 22, 404-420. doi:10.1016/j.nbd.2005.12.003
Cicchetti, F. et al. (2009) Environmental toxins and Parkinson's disease: What have we learned from pesticide-induced animal models? Trends in Phar- macological Sciences, 30, 475-483. doi:10.1016/j.tips.2009.06.005
Richardson, J.R. et al. (2009) Elevated Serum Pesticide Levels and Risk of Parkinson Disease. Archives of Neurology, 66, 870-875. doi:10.1001/archneurol.2009.89
Yoon, J. et al. (2009) Simulation studies on the stabilities of aggregates formed by fibril-forming segments of alpha-Synuclein. Journal Biomolecular Structure and Dynamics, 27, 259-270.